Celrixafor

Celrixafor (generic name: plerixafor) is an injection used to mobilize hematopoietic stem cells from the bone marrow into the bloodstream. It is primarily used in combination with granulocyte-colony stimulating factor (G-CSF) for the mobilization of stem cells in patients who are undergoing autologous stem cell transplantation. Stem cells are then collected and used for transplant, often in patients with certain cancers, like non-Hodgkin lymphoma and multiple myeloma.

Plerixafor works by blocking the CXCR4 receptor, which is responsible for retaining stem cells in the bone marrow. By inhibiting this receptor, Celrixafor allows stem cells to be released into the bloodstream, where they can be harvested more easily for transplantation.

Uses of Celrixafor

✅ Stem Cell Mobilization — Mobilizes stem cells for autologous stem cell transplantation.
✅ Cancer Treatment — Used in patients with cancers such as multiple myeloma and non-Hodgkin lymphoma who require stem cell collection.
✅ Bone Marrow Disorders — Helps collect hematopoietic stem cells for patients with hematological disorders.

Key Benefits

• Enhanced stem cell mobilization: Significantly improves the yield of stem cells, which can help with faster and more effective transplants.

• Effective for various cancers: Particularly useful in patients undergoing treatment for blood cancers like multiple myeloma and non-Hodgkin lymphoma.

• Easy administration: Given via subcutaneous injection, typically over a 4–5 day period, often in conjunction with G-CSF to optimize stem cell mobilization.

• Safety profile: When used as directed, Celrixafor is generally well tolerated, with manageable side effects.

How Celrixafor Works

Celrixafor (plerixafor) is a CXCR4 antagonist. The CXCR4 receptor plays a crucial role in the retention of hematopoietic stem cells in the bone marrow. By blocking this receptor, plerixafor allows these stem cells to be released into the bloodstream. This process, called mobilization, increases the number of stem cells that can be collected for transplantation.

Typically, Celrixafor is administered along with G-CSF (granulocyte-colony stimulating factor), which stimulates the production of white blood cells. The combination of these two medications maximizes the yield of stem cells and ensures their successful collection